SRC and gastric cancer: To further identify which signal transduction pathway(s) was involved in the mechanism behind IL‐8‐up‐regulated motility activity in human gastric cancer cells, we applied the following inhibitors such as LY294002 (Akt inhibitor), U0126 (ERK1/2 inhibitor), SB203580 (p38 MAPK inhibitor), SP600125 (JNK1/2 inhibitor), XAV939 (β‐catenin inhibitor) and PP2 (Src inhibitor) to, respectively, block these pathways in the presence of IL‐8.